Authorize and introduce parallel! Take stock of the nine biomedical cooperations in November: Hengrui Pharmaceuticals, Fuhong Hanxuan, etc. have innovative drug exports

According to incomplete statistics, at least nine Chinese companies reached a new drug research and development license in November.
, Hengrui Pharmaceuticals, Fuhong Hanxuan, Fuyon Pharmaceuticals, etc. all achieved the authorization of independent research and development products last month.
the same time, Soryuan Biological, Yuanda Pharmaceuticals, Thought Di Pharmaceuticals, Yourui Pharmaceuticals and other companies have introduced innovative products.
most of these products focus on the field of anti-tumor, targeting PD-L1, TGF-β, EGFR, 4-1BB, Bcl-2, etc.
this article, we've selected some of the most interesting licensing cases to see what innovative therapies and technologies are involved in these transactions.
November China Biopharmaceutical Company to participate in the authorized transaction case (incomplete statistics)1, the introduction party: DONG-A ST company authorized party: Hengrui pharmaceutical mechanism / target: PD-L1/TGF-β RII antibody picture Source: Reference: Dong-A ST, Inc., Korea, has obtained the exclusive clinical development, production and marketing rights of Hengrui Pharmaceutical Anti-Tumor Drug SHR-1701 in Korea and is licensed to develop and sell SHR-1701 for all human diseases.
according to the press release, SHR-1701 is a program-based death ligation 1 (PD-L1)/transformation growth factor-β type II (TGF-β RII) antibody developed by Hengrui Pharmaceuticals with intellectual property rights.
it can target both the PD-L1 path and the TGF-β path, it is expected to awaken and restore the body's anti-tumor response, thus playing a role in controlling tumor growth.
In China, SHR-1701 has been approved by the State Drug Administration (NMPA) to conduct a number of clinical studies, including advanced malignancies, advanced/metastatic pancreatic cancer first-line treatment, stage III non-small cell lung cancer (NSCLC) and so on.
, the product has initiated a number of clinical studies.
SHR-1701 license is also the third innovative drug hengrui Pharmaceuticals has exported overseas to China, according to public information.
2. Introducing Party: Binacea Pharma Authorizer: Fuhong Hanxuan Action Mechanism/Target: Dual-specific Antibody Fuhong Hanyu targeting EGFR and 4-1BB signed a licensing and co-development agreement with Binacea Pharma to license and jointly develop a dual-specific antibody HLX35 that can target both EGFR and 4-1BB.
HLX35 is a dual-specific antibody developed by Fuhong Hanxuan, targeting two targets, the peritoneal cell growth factor subject (EGFR) and 4-1BB (i.e. CD137).
is intended to be widely used in the treatment of colorectal cancer and head and neck tumors and other solid tumors.
, HLX35 is still in the preclinical development phase.
's research has shown that it can not only bind to EGFR molecules on the surface of the tumor, blocking tumor signaling pathfects and killing tumor cells, but also binding 4-1BB immune activation molecules on the surface of immune cells (T cells and NK cells) to allow more immune cells to gather around the tumor and stimulate the activity of immune cells in the micro-environment, thus acting as a synergetic killing of tumor cells to improve efficacy.
3. Introduction: Eli Lilly and Company Licensee: Reinsurgery Pharmaceutical Mechanism/Target: Bcl-2 Selective Small Molecule Inhibitor Fosun Pharma Subsidiary Fosun Pharma grants Lilly exclusive license to develop, register, produce and commercialize Bcl-2 Selective Small Molecule Inhibitor FCN-338 in all regions of the world except Chinese mainland, Hong Kong and Macau.
FCN-338 is the selected inhibitor of B-cell lymphoma-2 (Bcl-2).
Bcl-2 protein family plays an important role in apoptosis, which is the normal process of cell death.
FCN-338 was originally developed to treat malignant tumors in the blood system.
, Lilly executives have said the FCN-338 has great potential to benefit patients and become an important part of its anti-tumor pipeline, according to publicly available data.
plans to launch Phase 1 trials in the U.S. in the next few months, looking forward to obtaining clinical pharmacological data.
will also explore the potential of the FCN-338 with products in its pipeline, starting with the use of FCN-338 and LOXO-305.
4, the introduction party: Soyuan biological licensing party: Wu Chinese medicine mechanism / target: recombinant human vascular endotrogen sorrene biological access to Wu Chinese medicine class 1 anti-cancer new drug recombinant human vascular endoterotonin (now named DB108) outside china's global interests, including DB108 development, manufacturing, use, distribution exclusive license.
is a recombinant protein drug that inhibits tumor growth and metastasis by inhibiting angiogenesic production.
public information shows that DB108 is prepared with E. coli expression, the molecular weight is 20KDa, a total of 184 amino acids, the same as the natural human source of endo-corrosine amino acid sequence.
, DB108 has shown good safety and tolerance in phase 3 clinical trials in China for the first-line treatment of non-small cell lung cancer, and has shown significant efficacy in median non-progressive lifetimes.
As the first new drug to be introduced from a Chinese pharmaceutical company, the company will develop and produce targeted biomarkers through the all-gene scanning platform technology to predict db108 efficacy and bring DB108 to the global market through international clinical trials.
5, the introduction of: Great Pharmaceutical Licensing Party: Telix Group mechanism of action / target: Radionuclide Association Drug (RDC) GreatEr Medicine will be Telix Group with "first-in-class" potential of innovative RDC, the exclusive commercial promotion rights and production rights in Greater China.
include innovative RDC TLX591, TLX250, TLX101 for the treatment of prostate cancer, transparent cell nephroblastoma (ccRCC) and glioblastoma, and innovative RDC TLX591-CDx, TLX250-CDx, TLX599-CDx for tumor diagnosis.
according to public information, Yuanda Pharmaceuticals will start the clinical registration and declaration of the above-mentioned six authorized products in the agreement in Greater China.
the current progress of these projects is as follows: TLX591 has now completed clinical Phase 2 trials, entering preclinical phase 3 preparation in Australia and the United States, TLX591-CDx has completed clinical studies and filed a listing application with the FDA in September this year, and TLX250 is about to launch two Phase 2 clinical trials to assess the efficacy of ccRCC in combination with existing oncology immunotherapy, TLX250-CDx has been identified as a breakthrough therapy and is currently in Phase 3 clinical phase 3, and TLX101 combined exosome radiotherapy is currently conducting Phase 1/2 clinical trials in several hospitals in Europe and Australia.
6, the introduction party: Idea Di Pharmaceutical licensee: Aravive Company's mechanism of action / target: the new GAS6-AXL signal path pathrain inhibitor Thought Di Pharmaceuticals (3D Medicines) obtained the United States Aravive Company a new drug AVB-500 in the field of cancer in Greater China clinical development and commercial exclusive authorization.
AVB-500 is a specific, high affinity Fc fusion protein and is a new GAS6-AXL signaling pathogen inhibitor, which is considered one of the new targets for cancer treatment research.
preclinical studies, AVB-500 has been shown to neutralate the signaling path through binding gas6 to its activity.
, Aravive has successfully completed the AVB-500 phase 1b clinical trial in the United States for platinum-resistant ovarian cancer adaptation and is about to enter Phase 3 registered clinical studies.
same time, a number of clinical studies have been conducted on multiple adaptations such as transparent cell renal cell carcinoma.
it's worth noting that the product has been awarded fast-track status by the FDA for platinum-resistant relapsed ovarian cancer adaptation.
7, the introduction: Ulster Pharmaceutical licensor: Neumentum company mechanism of action / target: new intravenous infusion ketone acid preparation Urui Pharmaceuticals to obtain a new intravenous infusion ketone cric acid (NTM-001) in China research and development and commercial interests.
NTM-001 is a new, alcohol-free ketone hetic acid preparation that can be infused intravenously for 24 hours through an easy-to-use premixed bag.
the drug is commonly used in postoperative settings to treat moderate to severe acute pain that would otherwise require opioids for analgesics.
, NTM-001 is known to have no opioid-related risks and no drawbacks to high doses of short-acting ketone acid.
Yurui Pharmaceuticals said in an earlier press release that NTM-001 is a differentiated product that meets China's current unseeded needs, and that as a company focused on postoperative pain management, the addition of NTM-001 enhances Unreal's current product portfolio.
。